bz-423 has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lilla, C; Livingstone, E; Roesch, A; Schadendorf, D; Swann, S | 1 |
| Dourlat, J; Garbay, C; Gresh, N; Liu, WQ | 1 |
2 other study(ies) available for bz-423 and Melanoma
| Article | Year |
|---|---|
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydrazines; Imidazoles; Indoles; Melanoma; Metformin; Mitochondria; Oxidative Phosphorylation; Oximes; Phenformin; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2015 |
Novel 1,4-benzodiazepine derivatives with antiproliferative properties on tumor cell lines.
Topics: Antineoplastic Agents; Benzodiazepines; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Models, Chemical; Molecular Conformation | 2007 |